SEC Form 4 · accession 0001437749-26-019964
UroGen Pharma Ltd. · URGN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Mark Schoenberg
Officer — Chief Medical Officer
Period of report
Jun 8, 2026
Accepted (ET)
Jun 9, 2026 · 1:59 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001668243
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary SharesF1 | Jun 8, 2026 | M | 10,000 | — | A | 144,985 | D | |
| Ordinary SharesF2 | Jun 8, 2026 | S | 5,222 | $27.30 | D | 139,763 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitsF1,F3 | — | Jun 8, 2026 | M | 10,000 | D | — | — | Ordinary Shares | 10,000 | 0 | D |
Explanation of responses
- F1Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer.
- F2Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units.
- F3The reporting person was granted RSUs on June 8, 2023 representing 30,000 ordinary shares. The RSUs will vest in three equal annual installments from June 8, 2024.